In this week’s Pharma Pulse, the launch of the Ember Cube 2, exclusive policy insights from Asembia AXS26, a record-breaking ...
CoverMyMeds' Miranda Delatore and Megan Wetzel discuss AI in prior auth and fixing specialty access bottlenecks upstream. In ...
Scaling from ultra-rare volumes to mainstream indications threatens redundancy-heavy manufacturing and logistics, forcing ...
Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years. In his interview with ...
PBM reform is accelerating via FTC settlements and CAA 2026, mandating data reporting, rebate pass-through in Part D, ...
Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around specialty medicines.
At Asembia AXS26, Dee Chaudhary broke down how shifting US drug pricing policy is tightening payer controls and changing ...
Live from Asembia AXS26, Jessica Lovett explains what real world evidence and data matters most in making decisions around ...
Eli Lilly has entered a definitive agreement to acquire Kelonia Therapeutics for up to $7 billion. The centerpiece of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results